Actively Recruiting
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Led by Sohag University · Updated on 2025-07-30
100
Participants Needed
1
Research Sites
27 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
CONDITIONS
Official Title
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (≥18 years) diagnosed with primary ITP
- Receiving eltrombopag as part of their treatment
- Baseline liver function tests (LFTs) within normal limits
- Patients with diabetes
- Patients without diabetes
- Patients with fatty liver
- Patients without fatty liver
You will not qualify if you...
- Pre-existing liver disease (e.g., hepatitis, cirrhosis, non-alcoholic fatty liver disease)
- Concurrent use of hepatotoxic drugs
- Patients lost to follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sohag university hospital
Sohag, Egypt
Actively Recruiting
Research Team
P
Peter A Alfy, Resident
CONTACT
U
Usama M Abdelaal, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here